48 min
Measuring your arterial age to prevent heart diseases - Ted Baldwin - Imageens Impulse - Meeting Healthcare Pioneers
-
- Medicine
Cardiovascular diseases represent the leading cause of deaths worldwide. Despite the permanent progress in the treatment of such conditions, targeted prevention approaches remain a key solution to address this issue.
This is the challenge that Imageens, a Paris-based startup led by Ted Baldwin, is tackling through the application of artificial intelligence to medical imaging, with the aim to quantify your arterial age. This specific biomarker unvails unique opportunities to anticipate heart conditions for people at moderate risk, with the promise to inform better clinical care decisions.
We exchanged with Ted on the burden that cardiovascular diseases represent on a global level, the power of AI applied to medical imaging to discover early indicators of these pathologies, and how these insights can drive better personalized prevention programs to stay away from them.
Timeline:
(01:50) - The origins of Imageens
(06:23) - The unmet need that Imageens is addressing
(08:53) - Existing cardiac risk scores and the arterial age concept
(13:10) - Technical approach to quantify the arterial age using MRI and AI
(15:41) - Relationship between biological and arterial ages
(20:32) - The MESA trial led by Johns Hopkins University and its link to the discovery of cardiac risk scores
(23:26) - Imageens softwares Artfun+ and LABEL, their functioning and role in predictive imaging biomarkers discovery
(30:21) - Moving beyond MRI to other imaging modalities
(31:35) - Target patient population and access to Imageens technology
(33:43) - Acceptance by physicians and the medical community
(36:48) - Patient journey description
(38:00) - Moving towards predictive analysis of the optimal cardiac prevention program
What we also talked with Ted about:
Assistance Publique - Hôpitaux de Paris (AP-HP)
MESA trial
Framingham risk score
Cardiac CT calcium score
Ascending aortic distensibility
Ted’s TEDx presentation
Ganymed Robotics
Zoï
Altos Labs
Qualitiso
If you want to know more about Imageens, we invite you to consult their website: https://www.imageens.com/
You can contact Ted through LinkedIn or by email: tbaldwin@imageens.com
If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com
Cardiovascular diseases represent the leading cause of deaths worldwide. Despite the permanent progress in the treatment of such conditions, targeted prevention approaches remain a key solution to address this issue.
This is the challenge that Imageens, a Paris-based startup led by Ted Baldwin, is tackling through the application of artificial intelligence to medical imaging, with the aim to quantify your arterial age. This specific biomarker unvails unique opportunities to anticipate heart conditions for people at moderate risk, with the promise to inform better clinical care decisions.
We exchanged with Ted on the burden that cardiovascular diseases represent on a global level, the power of AI applied to medical imaging to discover early indicators of these pathologies, and how these insights can drive better personalized prevention programs to stay away from them.
Timeline:
(01:50) - The origins of Imageens
(06:23) - The unmet need that Imageens is addressing
(08:53) - Existing cardiac risk scores and the arterial age concept
(13:10) - Technical approach to quantify the arterial age using MRI and AI
(15:41) - Relationship between biological and arterial ages
(20:32) - The MESA trial led by Johns Hopkins University and its link to the discovery of cardiac risk scores
(23:26) - Imageens softwares Artfun+ and LABEL, their functioning and role in predictive imaging biomarkers discovery
(30:21) - Moving beyond MRI to other imaging modalities
(31:35) - Target patient population and access to Imageens technology
(33:43) - Acceptance by physicians and the medical community
(36:48) - Patient journey description
(38:00) - Moving towards predictive analysis of the optimal cardiac prevention program
What we also talked with Ted about:
Assistance Publique - Hôpitaux de Paris (AP-HP)
MESA trial
Framingham risk score
Cardiac CT calcium score
Ascending aortic distensibility
Ted’s TEDx presentation
Ganymed Robotics
Zoï
Altos Labs
Qualitiso
If you want to know more about Imageens, we invite you to consult their website: https://www.imageens.com/
You can contact Ted through LinkedIn or by email: tbaldwin@imageens.com
If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com
48 min